This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: PARADIGM-HF

March 2016 Br J Cardiol 2016;23:10–11

In brief

BJCardio Staff

Abstract

Approval for new heart failure treatment A breakthrough drug for the treatment of chronic heart failure is now available in the UK.  The new drug sacubitril/valsartan (Entresto®, Novartis) has been approved for the treatment of adults with symptomatic heart failure with reduced left ventricular ejection fraction (HFREF). Sacubitril/valsartan – the first drug in the angiotensin receptor neprilysin inhibitor (ARNI) class of drugs – was found to be superior to an evidence-based dose of the angiotensin-converting enzyme (ACE) inhibitor, enalapril, in the PARADIGM-HF study, the largest heart failure study conducted to date. PARADIGM-HF (Pros

| Full text
Cardiorenal medicine: challenges for the decade ahead

February 2016 Br J Cardiol 2016;23:(1) Online First

Cardiorenal medicine: challenges for the decade ahead

Thomas Gilpin, Amanda Laird

Abstract

Acute heart failure The first of the clinical heart failure sessions, delivered by Professor Theresa McDonagh (King’s College Hospital, London), considered the definition of acute heart failure (AHF) and how this has been simplified over recent years from a minefield of overlapping statements set out in 2008. Acute hypertensive heart failure, acutely decompensated chronic heart failure, acute coronary syndrome (ACS) and heart failure, right heart failure – amongst other terminology – have now been categorised into: ‘puffers’ – pulmonary oedema, fluid distribution error and ‘bloaters’ – peripheral oedema with genuine fluid

| Full text

February 2016 Br J Cardiol 2016;23:(1) Online First

News from the BSH 18th Annual Autumn Meeting

Parminder Chaggar, Matthew Kahn

Abstract

Bridging the gap: from trials to inner cities Within the field of heart failure, there is a breadth of prognostic therapies derived from large, randomised controlled trials. Professor Iain Squire (Glenfield Hospital, Leicester) described how new treatments require approval in the European Union before they can be implemented into clinical practice within the member states. The European Medicines Agency (EMA) ensures the best use of scientific resources across Europe. While certain classes of technologies must undergo licencing via a centralised procedure, most therapies will be eligible for licensing by one member state on behalf of other na

| Full text

December 2015 Br J Cardiol 2015;22:143–4

In brief

BJCardio Staff

Abstract

BHF to spend half a billion pounds on research A new research strategy has been launched by the British Heart Foundation (BHF), aiming to fund over half a billion pounds of new cardiovascular research over the next five years. The BHF’s new strategy includes a commitment to continue funding the best researchers working across all areas of cardiovascular disease research.  This includes a pledge by the BHF to help women stay in research after a review highlighted the underrepresentation of women in senior cardiovascular research roles. Also, for the first time, the BHF will fund healthcare professionals, such as nurses, by establishing a de

| Full text
News from the Cardiorenal Forum 9th Annual Scientific Meeting – embracing the future, not forgetting the past

March 2015 Br J Cardiol 2015;22:17

News from the Cardiorenal Forum 9th Annual Scientific Meeting – embracing the future, not forgetting the past

Dr Legate Philip

Abstract

Managing risk factors – the old offenders Diet An update on diet and cardiovascular disease was given by Professor Kay Tee Khaw (University of Cambridge). A surprise recent finding has been that increased body mass index (BMI) trends do not directly correlate with cardiovascular mortality, particularly in Mediterranean countries (figure 1). Figure 1. Body mass index and associated coronary heart disease in Europe. Panel a) body mass index; panel b) coronary heart disease This gives rise to the question: is diet a key moderating factor in the relationship between BMI and cardiovascular mortality? The PREDIMED (Effects of the Mediterranean Di

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now